YuanYuanMD

Clinical Trials

• Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer Start of enrollment: 2008 Sep 04

  Completed

• Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2010 May 17

  Completed

  Phase 1

• Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer Start of enrollment: 2012 Feb 15

  Active, not recruiting

  Phase 2

• Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Start of enrollment: 2014 Oct 01

  Completed

  Phase 1

• Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer Start of enrollment: 2016 Dec 02

  Completed

  Phase 2

• Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer Start of enrollment: 2016 Sep 30

  Recruiting

  Phase 2

• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Start of enrollment: 2017 Jun 01

  Completed

  Phase 2

• Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer Start of enrollment: 2019 Mar 04

  Completed

  Phase 1, Phase 2

• Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer Start of enrollment: 2023 Oct 13

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator, Contact

• CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer Start of enrollment: 2021 Oct 18

  Active, not recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• Join now to see all